Nanobac Pharmaceuticals Return on Equity

Nanobac Pharmaceuticals (NNBP) currently reports a ROE of 278.38%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Nanobac Pharmaceuticals's ROE history and peer comparisons.

Nanobac Pharmaceuticals's ROE of 278.38% is higher than the Healthcare sector average of -100.59%. That is roughly 376.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Nanobac Pharmaceuticals's current 278.38% should be judged against Healthcare norms (sector average: -100.59%) and against NNBP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 278.38%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Nanobac Pharmaceuticals, and consider following NNBP for alerts when major investors trade the stock.

Nanobac Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 278.38% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NNBP with unrelated industries.